See the Full Picture.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Cannes Film Festival
Social Media
Eurovision
Vladimir Putin
Donald Trump
European Union
Stock Markets
Education
Golf
Cricket
Amazon
Published • loading... • Updated

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Summary by CNHI News
DA-1241 Significantly Decreased Plasma ALT levels, with a Mean Reduction of 22.8 U/L After 16 Week-Treatment

2 Articles

All
Left
1
Center
Right
Kilgore News HeraldKilgore News Herald
Reposted by
CNHI NewsCNHI News
Lean Left

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

DA-1241 Significantly Decreased Plasma ALT levels, with a Mean Reduction of 22.8 U/L After 16 Week-Treatment

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

CNHI News broke the news in United States on Wednesday, May 7, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Kilgore

Kilgore

News
For You
SearchBlindspotLocal